Abstract
OBJECTIVE
Peptide receptor radionuclide therapy (PRRT) is dependent upon binding of radiolabelled peptides to their respective receptor expressing cells. The main objective of this study was to characterize the expression of somatostatin receptor (SSTR) subtypes in non-medullary thyroid cancers in order to be able to recommend the use of PRRT as a treatment option in patients with progressive local or metastatic disease.
DESIGN
We constructed tissue microarrays from paraffin blocks prepared from 47 cases of non-medullary thyroid carcinomas and related normal thyroid tissue. Immunohistochemical staining was performed with five different polyclonal SSTR antibodies.
RESULTS
SSTR subtypes sst2 and sst3 were expressed in all non-medullary thyroid carcinomas, sst1 and sst5 in 75%, and sst4 in 38%. Coexpression of more than three subtypes was detected in 36 of the 47 cases. The expression of SSTR sub-types in normal thyroid tissue was low or absent.
CONCLUSIONS
Non-medullary thyroid carcinomas frequently express all SSTR subtypes. This expression provides a basis for further studies with the aim of exploring PRRT as a possible new treatment for iodine-131 refractory metastatic non-medullary thyroid carcinomas.
Article PDF
Similar content being viewed by others
References
Hundahl SA, Fleming ID, Fremgen AM, Menck HR, 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 15: 2638–2648.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium and the European Thyroid Cancer Taskforce. Eur J Endocrinol 154: 787–803.
Sherman SI, 2003 Thyroid carcinoma. Lancet 8: 501–511.
Maxon HR 3rd, Smith HS, 1990 Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 19: 685–718.
Janson ET, 2006 Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary 9: 249–256.
Teunissen JJ, Kwekkeboom DJ, Krenning EP, 2006 Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 17: 19–25.
Garin E, Devillers A, Le Cloirec J, et al, 1998 Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 25: 687–694.
Valli N, Catargi B, Ronci N, et al, 1999 Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 9: 583–589.
John M, Meyerhof W, Richter D, et al, 1996 Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38: 33–39.
Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR, 2011 Radiopeptide imaging and therapy in Europe. J Nucl Med 2: 42S–55S.
Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V, 2012 Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine :DOI 10.1007/s12020-012-9631-1.
Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D, 2010 Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res 42: 237–240.
Pisarek H, Stepien T, Kubiak R, Borkowska E, Pawlikowski M, 2009 Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohisto-chemical and molecular biology (RT-PCR) investigation. Thyroid Research 2: 1–8.
Sancak S, Hardt A, Singer J, et al, 2010 Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves’ disease. Thyroid 20: 505–511.
Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC, 2001 Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 54: 641–649.
Ludvigsen E, Olsson R, Stridsberg M, Janson ET, Sandler S, 2004 Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 52: 391–400.
Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H, 2005 Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 52: 605–611.
Diakatou E, Kaltsas G, Tzivras M, Kanakis G, Papaliodi E, Kontogeorgos G, 2011 Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study. Endocr Pathol 22: 24–30.
Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K, 2010 SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol 1: 142–147.
Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A, 2001 Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 11: 647–659.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pazaitou-Panayiotou, K., Janson, E.T., Koletsa, T. et al. Somatostatin receptor expression in non-medullary thyroid carcinomas. Hormones 11, 290–296 (2012). https://doi.org/10.14310/horm.2002.1357
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1357